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Abstract: Oncolytic adenovirus (Ad) vectors present a new modality to treat cancer. These 
vectors attack tumors via replicating in and killing cancer cells. Upon completion of the 
vector replication cycle, the infected tumor cell lyses and releases progeny virions that are 
capable of infecting neighboring tumor cells. Repeated cycles of vector replication and cell 
lysis can destroy the tumor. Numerous Ad vectors have been generated and tested, some of 
them reaching human clinical trials. In 2005, the first oncolytic Ad was approved for the 
treatment of head-and-neck cancer by the Chinese FDA. Oncolytic Ads have been proven to 
be safe, with no serious adverse effects reported even when high doses of the vector were 
injected intravenously. The vectors demonstrated modest anti-tumor effect when applied as 
a single agent; their efficacy improved when they were combined with another modality. 
The efficacy of oncolytic Ads can be improved using various approaches, including vector 
design, delivery techniques, and ancillary treatment, which will be discussed in this review. 
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1. Introduction  
In spite of tremendous advances in the prevention, diagnosis, and therapy of cancer, it is the second 
most frequent cause of mortality in the United States. Many forms of cancers are considered to be 
incurable, and treatment for many tumors results in only a minor increase in the time of survival. 
Further, these treatment regimes cause serious side effects; some patients decide to receive palliative 
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treatment only. It is not surprising that researchers continuously work to develop new modalities for 
anti-cancer therapy.  
One such new method uses genetically modified oncolytic (replication-competent, RC) adenovirus 
(Ad) “vectors” [1]. The first application of Ads in gene therapy was their use as replication-defective 
(RD) carriers to introduce foreign genes into target cells. Oncolytic Ads, on the other hand, replicate in 
the target tumor cells and kill these cells by virtue of replicating in them. The replication of the vector 
results in the release of progeny virions that can infect adjacent tumor cells and amplify the effect. In 
theory, the infecting oncolytic virus can spread through a solid tumor and eliminate it in the process. 
The reasons for the popularity of Ad as a gene therapy vector are manifold. The biology of natural 
Ad infection in humans is quite well understood (reviewed in [2]), and information is available as well 
about  experimental  infection  of  humans  with  Ads  and  Ad  vectors  (reviewed  in  [3]).  Also,  the 
molecular biology of the virus is well studied; Ads were used as a model organism to study DNA 
replication,  mRNA  processing,  oncogenic  transformation,  and  apoptosis  (reviewed  in  [4,5]).  The 
replication of the virus and its effect on the host cell and the host immune system have been examined 
in great detail. 
It is known from decades of basic research with Ads that the virus is genetically stable, and methods 
for engineering Ad vectors and producing of large quantities of high-titer stocks have been established. 
The relatively small double-stranded DNA genome lends itself for easy manipulation, either directly or 
cloned into bacterial plasmids [6,7]. Ads infect a wide variety of cells, quiescent or replicating, and the 
integration of viral DNA into the host genome is rare. Further, human type 5 Ad (Ad5), the serotype 
most frequently used as the parental virus for vector construction, causes asymptomatic or mild, self 
resolving illness in infants that results in long-term immunity to the virus [2]. Ad5 causes little, if any 
disease in immunocompetent adults. Thus, the danger to the treated patient is relatively low, as is the 
chance of an epidemic started from vector shed from the patient.  
To increase the safety of Ad vectors, various modifications have been introduced to restrict vector 
replication to tumor cells. Most of these modifications exploit defects in certain signal transduction 
pathways in cancerous cells, e.g. delete viral genes regulating pro-apoptotic cellular functions known 
to be inactive in tumor cells, replace promoters for essential viral genes with promoters that are active 
only in tumor cells, or disable the vector’s capacity to promote the infected cell to a proliferative state 
(reviewed  in  [8]).  Some  oncolytic  Ads  embody  a  combination  of  these  methods  to  achieve  more 
stringent control of replication.  
2. Preclinical studies with oncolytic Ads 
In the past one and a half decades, many laboratories have worked to construct oncolytic Ad vectors 
and evaluate them in preclinical studies and clinical trials. Preclinical results with the efficacy of 
oncolytic  Ads  are  promising:  the  vectors  impeded  the  growth  of  the  tumors  or  even  completely 
eliminated several treated tumors in animal models [9-13]. Tumors of various origin were tested in 
subcutaneous,  disseminated,  and  orthotopic  models,  with  the  vector  injected  intratumorally, 
intracavitally, or intravascularly. Further, oncolytic Ads were reported to be remarkably safe in these 
animal studies. To elicit toxicity, researchers injected the virus intravenously in large doses [11,14]. 
The results of these experiments have been extensively reviewed [15-18]. As an example, we discuss 
results  with  ONYX-015  (dl1520)  [9]  because  this  is  the  oncolytic  Ad  with  the  most  extensive Viruses 2010, 2                           
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literature. Further, ONYX-015 was the first replication competent anti-tumor Ad vector tested, and as 
such, still serves as a benchmark for efficacy and safety for other oncolytic Ads with enhanced anti-
tumor efficacy.  
The original underlying rationale for the design of ONYX-015 is that since nearly all tumors have 
defective  p53  pathways,  E1B  55K,  the  anti-apoptotic  viral  protein  responsible  for  binding  and 
inactivating p53 and thus preventing virus-infected cells from undergoing apoptosis, is dispensable in 
cancer  cells.  Thus,  with  ONYX-015,  the  gene  for  the  E1B  55K  protein  is  deleted.  Therefore,  
ONYX-015 was expected to be able to replicate in p53
- tumor cells, but induce apoptotic cell death 
and  abortive  infection  in  p53
+  normal  cells.  Although O N Y X -015  was  shown  to  replicate 
preferentially  in  cancer  cells,  later  publications  disproved  this  proposed  mechanism  for  cancer 
specificity [19]. It was demonstrated that rather than distinguishing cancer cells from normal cells by 
their p53 status, the cancer specificity of ONYX-015 stems from a defect in the export of Ad mRNA 
from the nucleus (which is another function of E1B 55K) [20], which is complemented by the up-
regulation of heat-shock protein expression in many tumor cells [21]. Upon intratumoral, intravenous, 
or  intraperitoneal  injection,  ONYX-015  replicated  in  and  suppressed  the  growth  of  subcutaneous 
human tumor xenografts in nude mice [9-11]. The anti-tumor efficacy of the vector increased when 
virotherapy was combined with the administration of chemotherapeutic agents, resulting in complete 
regression of tumors [22]. When injected intratumorally, ONYX-015 titers increased 100- to 1000-fold 
over 72 h, and vector spread within the tumor was strongly influenced by the original distribution and 
by the tumor microenvironment [23]. In an experiment in which cancer cells mixed with cancer cells 
infected with the vector at various ratios were used to generate subcutaneous tumors, preinfection of 
5% of cells was sufficient to prevent tumor formation [23]. With mice, no toxicity was reported with 
intratumoral injection of ONYX-015. Intravenous injection of the vector caused liver toxicity with a 
maximum tolerated dose of 1.7 x 10
9 plaque forming units, fractionated into five daily doses [11].  
Much of the results obtained with ONYX-015 can be generalized for the oncolytic Ad field. Results 
with  the  newer  vectors  with  enhanced  anti-cancer  properties  will  be  discussed  in  the  appropriate 
sections later in the article. However, certain concerns with the animal models used to obtain the data 
will be reviewed below. 
In  preclinical  efficacy  studies,  most  data  have  been  gathered  using  the  human  xenograft-
immunodeficient (nude, SCID, etc.) mouse model. With this model, human tumor cells, most often 
from permanent cell lines, are injected to generate tumors in the mice, which allow the growth of these 
tumors  because  of  the  mouse’s  immunodeficient  status.  The  oncolytic  Ad  can  be  injected 
intratumorally  or  systemically,  and  the  efficacy  of  the  vector  is  determined  by  measuring  the 
progression  of  the  tumor.  Tumor  growth  and/or  vector  distribution  can  be  monitored  by  in  vivo 
imaging techniques. The need for the highly artificial nude mouse model stems from Ads species-
specific nature, i.e., that oncolytic Ads of human origin replicate poorly in standard laboratory rodents. 
With this system, the virus can replicate in the human tumor xenograft, but not in the normal organs of 
the host. Also, as the mice used are immunodeficient, the immune response to the vector and the tumor 
cannot  be  investigated.  For  safety  studies,  the  test  animals  of  choice  have  been  C57BL/6  mice, 
probably because this mouse strain was extensively used for testing the safety of RD gene therapy 
vectors. Using mice, one can study the immediate toxicity caused by host response to the input virus Viruses 2010, 2                           
 
1847 
capsids (reviewed in [24]). However, mice have a limited utility to test virus replication in normal 
organs and toxicity resulting from virus replication.  
To overcome the shortcomings of using mice as an animal model, we [12,25] and others [26,27] 
have adopted a permissive, immunocompetent animal model based on the Syrian hamster. Human Ad5 
replicates in several hamster cell lines, reaching a burst size between one-tenth and one-hundredth of 
the burst size in the human A549 lung cancer cell line, which is one of the most permissive cell lines 
available [25]. In vivo, Ad5 and Ad5-derived vectors replicate in various organs of the hamster, most 
prominently in the liver. The hamster cell lines can be used to form tumors in immunocompetent 
animals. In this model, we demonstrated that immunocompetent animals quickly develop immunity 
against the vector, and that this immunity has a deleterious effect on the efficacy of an oncolytic  
Ad [28].  
In addition to anti-tumor activity, hamsters offer a good model to test the biodistribution [29] and 
toxicity  [14]  of  the  RC  Ad  vectors.  After  intravenous  injection  into  hamsters,  Ad5-based  vectors 
distributed widely to all tested organs. Up to a week after injection, the DNA of a RC Ad vector was 
more abundant than that of a RD vector, and live, infectious RC but not RD vector could be isolated 
from the lung and liver of infected hamsters. The viral DNA content of the tested organs declined 
steadily  afterward,  but  it  could  be  detected  in  several  organs  even  one  year  after  virus  injection. 
Surprisingly, at this late time, the same amount of RD and RC Ad DNA could be recovered from the 
animals. As no live RD vector was recovered from the animals 24 h after injection, the most likely 
explanation is that the real-time PCR assay detected naked viral genomes, or genome fragments, which 
persist in the tissues. These data point out the limitations of real-time PCR; for RC vectors, assaying 
for infectious vector results in more meaningful data. Supporting the findings of the biodistribution 
experiment, in hamsters, intravenous injection of the RC vector caused more liver damage than that of 
the RD vector [14]. No such difference was observed in mice, which indicates that the toxic effects of 
RC Ads are at least partially due to virus replication.  
Another interesting result gained from the hamster studies is that immunocompetent animals cleared 
infectious Ads by approximately one week post injection and completely recovered from virus toxicity 
by four weeks post injection [14,29,30]. In contrast, large amounts of live virus could be recovered 
from  the  liver  of  immunosuppressed  hamsters  seven  days  post  injection,  and  about  50%  of  these 
animals succumbed to the infection [30], indicating that the host immune system plays a major role in 
eliminating Ad infection. This finding has major implications for the efficacy and safety of RC Ad 
vectors, as it will be discussed below.  
3. Clinical studies with oncolytic Ads 
Most clinical trials conducted with oncolytic Ad vectors have been Phase I dose escalation safety 
studies [31], but a few vectors entered more advanced stage Phase II and Phase III trials. The bulk of 
the data reported deals with the safety of the vectors. Thus far, no dose limiting toxicity has been 
reported with any of the trials, and adverse events were mild, allaying safety concerns about oncolytic 
Ads. Generally, it is believed that when the vectors were used as a single modality, efficacy was 
modest, but much better results were achieved when treatment with the vectors was combined with 
radiation treatment or chemotherapy. However, no solid conclusions can be drawn about the efficacy 
of these vectors as such data are much more scarce and harder to interpret because most of these trials Viruses 2010, 2                           
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were designed as dose escalation safety studies, and assessing vector efficacy was only a secondary 
goal. Besides, some clinical symptoms (the swelling of the tumors after vector injection, see below) 
may have been misinterpreted, further skewing the results. 
The vector with the most published clinical data is ONYX-015, which was evaluated in Phase I and 
II trials for a variety of indications, using intratumoral, intravenous, intra-arterial, and intraperitoneal 
routes  (reviewed  in  [32,33]).  An  oncolytic  Ad  virtually  identical  to  ONYX-015,  named  H101 
(Oncorine), was approved in China in 2005 for treatment of head and neck squamous cell carcinoma 
[34-37]. ONYX-015 was reported to be very safe; no dose-limiting toxicities were reached even in a 
study  in  which  3  ×  10
11  plaque  forming  units  (PFU)  of  ONYX-015  was  injected  intravenously, 
followed by five intratumoral injections [38]. The most-often reported adverse effect was a flu-like 
symptom, observed in most patients. In these trials, the efficacy of the vector was moderate [32,33]. 
The most promising data with ONYX-015 regarding its anti-tumor efficacy were reported by Dr. Tony 
Reid and colleagues. Dr. Reid treated colorectal metastases to the liver with injection of ONYX-015 
directly into the hepatic artery in combination with 5’-FU/leucovorin, resulting in tumor regression in 
46%  of  the  patients  [39-43].  Median  survival  rose  to  19  months,  from  the  expected  4-6  months 
survival observed in non-treated patients. Most interestingly, in some responders, tumor regression 
followed an acute enlargement of tumors [40-42]. While these tumors initially increased in size as 
detected by CT scans, PET imaging revealed that they had very low metabolic activity. This suggests 
that most of the tumor mass detected by CT scan might have been necrotic. With the majority of 
clinical trial protocols, in which PET imaging is not applied, this initial swelling would have been 
reported as progressive disease, missing the possible positive effect. Thus, multi-modal monitoring of 
the patients treated with oncolytic Ads is a must.  
Similar safety and efficacy data were published with two other groups of oncolytic Ad vectors. The 
first group of vectors has the same e1b-55K deletion as ONYX-015 but also express a fusion protein 
consisting of a cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) prodrug-
converting enzymes (reviewed in [44]). These vectors were used to treat prostate tumors by direct 
injection of the vector followed by prodrug administration. In some cases, the oncolytic Ad treatment 
was combined with radiotherapy. The results of two Phase I clinical trials have been published with 
these  vectors.  [45-47].  The  data  indicate  that  following  intra-prostatic  injection  the  vectors  were 
remarkably non-toxic, and have provided measurable clinical benefit to a stratum of patients (those 
with intermediate disease risk). 
The other family of oncolytic Ad vectors with data in the public domain about clinical trials is also 
designed to treat prostate cancer. The replication of these RC Ads is restricted to PSA-positive (i.e., 
prostate)  cells  by  replacing  the  original  viral  promoters  of  essential  viral  genes  for  PSA  and  rat 
probasin promoters. The vectors produced low toxicity, no DLTs, no MTD at vector doses up to 10
13 
virus particles (vp) after intra-prostatic injection [48,49] and 3 x 10
12 vp after intravenous injection 
[50], and some patients showed a decline in PSA levels [50].  
Recently, information about the results of clinical trials with a family of oncolytic Ads has become 
available. In one version of the vector, named Ad5/3-Cox2L-D24, the Ad5 fiber gene was substituted 
with that of Ad3 to achieve CAR-independent attachment. For tumor specificity, the vector has a 24 bp 
deletion in the e1a gene, abrogating its binding to the Rb family proteins, and the expression of e1a is 
regulated  by  the  cyclooxygenase  2  promoter  [51-53].  Another  version  of  this  vector,  named  Viruses 2010, 2                           
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ICOVIR-7, has the same e1a deletion, wild-type e1a promoter, and it has an RGD peptide inserted into 
the HI-loop of the Ad5 fiber protein instead of Ad3 fibers [54]. The third vector in this family has 
wild-type e1a promoter, the same e1a deletion, wild-type fiber, and it expresses GM-CSF [55]. All the 
three  vectors w ere  tested  in  patients  with  various  solid  tumors,  demonstrating  low  toxicity  and 
objective responses in approximately 60% of patients. 
4. Enhancing the efficacy of oncolytic vectors 
From the data delineated above, it is clear that there is an inconsistency between the efficacy data 
obtained  from  tissue  culture,  animal  experiments,  and  clinical  trials.  Tissue  culture  results  do  not 
translate directly to animals. Even when a particular vector kills a given cell line very efficiently in 
vitro, tumors formed using this cell line may not get eliminated completely. Multiple factors can cause 
this discrepancy between in vitro and in vivo data. Some observations indicate that virus spread within 
tumors is limited. After injection, oncolytic Ad-infected cells make up just a minor fraction of the 
tumor mass, usually clustered around the needle track, and infectious virus titers in tumors decrease 
rapidly [56]. Tumor architecture can be a major barrier to vector spread. In tissue culture monolayer, 
which is practically two-dimensional, the virus has ready access to all infectable cells; in contrast, 
tumors can be heavily compartmentalized. Thus, even if the vector efficiently eliminates all tumor 
cells within a compartment, fibrotic septa and necrotic areas may prevent its spread to the neighboring 
compartment of live tumor cells. In addition, in immunocompetent animals, and expectedly in patients, 
the immune system eliminates most of the virus in 14 days after virus injection [28].  
The  immune  response  to  the  vector  may  contribute  to  the  worse  than  anticipated  efficacy  of 
oncolytic Ads in clinical trials. As discussed above, most vector efficacy data were gathered in the 
immunodeficient mouse-human tumor xenograft model, in which the efficacy of the vector is not 
affected by anti-viral immunity. Further, oncolytic Ad clinical trials usually have been carried out with 
terminal patients who went through multiple rounds cancer therapy. These tumors are usually very 
large, heavily compartmentalized, necrotic, and are refractory to conventional treatment. This is in 
great contrast to the small subcutaneous tumors injected in most animal experiments.  
Thus,  while  oncolytic  Ads  have  been  proven  safe  without  a  doubt,  their  efficacy  warrants 
improvement. Below we summarize the approaches researchers have taken to increase the anti-tumor 
effects of oncolytic Ads. 
5. Selecting for the Ad with the best anti-tumor features 
Gain-of-function mutations in the viral genome result in more efficient anti-tumor agents. One 
approach to generate such a vector is to start with a pool of Ads of various serotypes, which are then 
repeatedly passaged on cancer cell lines at low multiplicity. This procedure will select for the fastest-
spreading virus. Such a procedure resulted in the isolation of an Ad3/Ad11 chimera with superior 
oncolytic features [57]. Alternatively, oncolytic Ad vectors with superior growth characteristics on 
cancer cell lines can be obtained by random mutagenesis and propagation of the resulting mutants on 
cancer cells, selecting for the fastest-growing isolate [58-60].  Viruses 2010, 2                           
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6. Avoiding over-attenuation of the vector 
In the initial phase of vector development, the priority for designing RC Ad vectors was safety. 
Vector replication was restricted to cancerous cells by modifying the Ad genome. However, these 
modifications caused some oncolytic vectors to replicate less well in cancer cells than did the parental 
wild-type Ad5. Inasmuch as the premise of oncolytic virotherapy is that the vector replicates and 
spreads in the infected tumor, this attenuation inevitably decreased anti-tumor efficacy.  
We reason that extensive attenuation of the vector (and the consequent decrease in efficacy) is not 
necessary. First, it has been demonstrated that Ads replicate preferentially in cells with de-regulated 
cell  cycle  [61].  Second,  most  clinical  protocols  call  for  intratumoral  injection  of  the  vector.  The 
circulating neutralizing antibodies, present in most adults, are very efficient in neutralizing virions 
escaping into the blood stream [30,62]. Third, most oncolytic Ads are derived from species C Ads, and 
infections with these Ads are mostly asymptomatic in immunocompetent adults [2]. Fourth, even in the 
unlikely  case  of  uncontrolled  disseminated  infection,  anti-viral  drugs  can  be  used  to  inhibit  Ad 
replication and thus limit the severity of disease [30]. To this effect, we have constructed VRX-007 
(also known as INGN 007), an oncolytic Ad5-based vector without engineered attenuating features 
[63].  VRX-007  has  the  genes  for  the  immunomodulatory  E3  proteins  [64]  deleted,  which  further 
increases its safety. VRX-007 overexpresses the adenovirus death protein (ADP, see below) to speed-
up its cell-to-cell spread. We compared the efficacy of VRX-007 to another oncolytic Ad named KD3 
[13]. KD3 is the parental vector of VRX-007, and it is identical to VRX-007 except that KD3 was 
engineered to replicate preferentially in cells with a deregulated cell cycle due to two small deletions in 
the e1a gene [65,66]. In vitro, VRX-007 has a broader host range than KD3 [13]. In vivo, the two 
oncolytic Ads were equally efficacious in some tumor models; however, in a challenging intravenous 
administration  model  VRX-007  clearly  outperformed  KD3,  and  was  also  significantly  more 
efficacious that ONYX-015 [13]. Toxicology and biodistribution experiments validated our original 
tenet, inasmuch as the safety profile of VRX-007 was similar to that of Ad5 in both permissive and 
non-permissive animal models [14,29]. VRX-007 is presently being tested in a Phase I clinical trial for 
intratumoral injection into solid tumors of any indication. 
7. Better delivery of the infecting bolus of vector  
Evidently, the more that the injected vector actually reaches tumor cells, the better the expected 
anti-tumor efficacy. The physical delivery of RC Ads to tumor cells is made difficult by multiple 
factors.  As  discussed  above,  most  solid  tumors  have  a  very  complex  architecture,  with  barriers 
preventing the spread of the vector throughout the tumor. Researchers and clinicians have been trying 
to  circumvent  this  obstacle  by  better  distributing  the  Ad  vector  within  the  tumor  using  multiple 
injections [67] or injecting the vector into the artery supplying the tumor [68]. Another approach is to 
try to modify the tumor matrix by expressing transgenes so that the matrix is more permeable for virus 
spread; this method will be discussed below. Treatment of superficial bladder cancer with oncolytic 
Ads has been contemplated [69]. It was shown that a glycosaminoglycan layer covering the inner 
surface of the bladder that inhibits Ad attachment. Eliminating this layer using detergents improved the 
infection rate and efficacy of Ad vectors [70,71].  Viruses 2010, 2                           
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Ad vectors can be delivered to tumors using mesenchymal stem cells (MSC) as delivery vehicles. 
MSCs can be productively infected with Ads [72], and were shown to home to tumors upon systemic 
delivery (for a review, see [73]). Thus, intravenously injected MSCs infected with oncolytic Ads seek 
out  tumors,  where  they  will  lyse  and  release  the  vector.  Ad5/3  fiber-chimeric  Ad-infected  MSCs 
homed to intraperitoneal ovarian tumors in mice after intraperitoneal injection and provided survival 
benefit over injection of Ad5/3 alone [72]. It was also demonstrated that when injected intravenously 
into orthotopic lung and breast cancer models in nude mice, MSCs infected with an Ad vector showed 
increased  efficacy  compared  to  the  same  vector  injected  alone,  even  though  accumulation  of  the 
injected MSCs at tumor sites could not be demonstrated [74]. 
Beyond the mere physical delivery of a virus particle to a tumor cell, infection also depends on the 
presence  of  cell  surface  receptors.  The  primary  receptor  for  Species  C  Ads  is  the  Coxsackie-
Adenovirus common Receptor (CAR), which, although expressed on many cell types, is low or is 
absent from certain tumors (e.g. bladder and ovarian cancer) [75,76], rendering these tumors poorly 
infectable by species C Ads. However, Ads can infect tumors in a CAR-independent manner [77,78]. 
Unfortunately, some of the same non-CAR-mediated processes are responsible for the predisposition 
of Ads to infect hepatocytes [79]. Although it has been shown that intravenous administration of an 
oncolytic Ad can be efficacious [52], the liver tropism of oncolytic Ads is widely believed to be a 
hindrance  for  systemic  delivery  of  the  vector;  besides  the  liver  toxicity,  the  anti-viral  efficacy 
decreases because only a fraction of the vector reaches the intended target. Researchers tackle these 
obstacles by either genetically- or chemically-modifying the capsid of the vector, and thereby targeting 
the  vector  to  tumors  through  selective  transduction.  Transductional  targeting  of  oncolytic  Ads  by 
genetic modification of the fiber knob, using bi-specific adapter molecules, and chemical modification 
of the capsid is the subject of many excellent reviews [80-83]. Here we will review some of the 
methods researchers used to target vector binding to specific cells. 
To extend the host range of an Ad vector to cells with little or no CAR expression, researchers 
swapped the fiber of a Species C-based vector to that of a Species B Ad [84]. Species B Ads use cell 
surface proteins other than CAR, such as CD46 [85] or CD80/86 [86] to infect the host cell. These 
receptors are present on some cell types on which CAR is absent (most notably ovarian cancer cells), 
thus allowing these Species C/B pseudotyped vectors to infect cells that are poorly infectable with 
Ad5-based  vectors.  Another  approach  changes  only  the  receptor-binding  surfaces  of  the  fiber  by 
inserting short peptide sequences, like a polylysine tract or the arginine-glycine-aspartate (RGD) motif 
of penton base, into the HI loop [87] or carboxyl terminus of the molecule [88]. Vectors carrying such 
modifications  were  able  to  infect  cells  with  heparan  sulfate  glucosaminoglycans  [88]  and  avβ3-5 
integrins [87] on their surface. While several laboratories generated Ad vectors with more specific 
peptide  ligands  in  their  capsid  proteins  [89-91], i t  was  found  to  be  very  difficult  to  predict  if 
incorporation of a given ligand will target the vector to the desired cells [92]. 
Others constructed virions bearing chimeric fibers that contain domains of structurally homologous 
proteins from other, phylogenetically distant viruses like bacteriophage T4 or reovirus [93,94]. To 
provide targeting specificity, they attached single-chain antibodies [95] or CD40 ligand [96] to these 
synthetic fibers.  
Genetic capsid modifications like the ones mentioned above have resulted in extending the host 
range of the parental vector. However, they did not change the vector’s predilection to infect the liver 
when administered systemically. In vivo, Ads can infect cells in a CAR-independent way through some 
plasma proteins binding to both the viral capsid and certain cells, serving as adaptor molecules to Viruses 2010, 2                           
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facilitate the infection of these cells. Most importantly, coagulation factor X (FX) binds both the Ad 
hexon protein and heparan-sulfate proteoglycans on hepatocytes [97,98]. As this binding proves to be a 
major factor behind Ads’ tropism for the liver, the modification of fiber only is insufficient to prevent 
the vectors’ natural tropism. Mutating the recently identified factor X binding sites on the Ad5 hexon 
proteins seems to have solved this problem [99].  
Chemical  modification  of  the  virions  can  result  in  altered  tropism  as  well.  The  fundamental 
difference between this method and the genetic modifications discussed above is that while the genetic 
modifications are present in the progeny virions as well, chemical modification affects only the input 
bolus  of  virions.  The  same  caveat  applies  to  all  similar  designs  such  as  Ad-liposome  complexes 
[100,101], and bispecific ligands [102,103]. With chemical modification, the virion is coated with a 
hydrophilic  polymer,  most  often  with  polyethylene  glycol  (PEG)  or  poly-N-(2-hydroxypropyl) 
methacrylamide (pHPMA) (reviewed by Kreppel [104]). This “shield” will protect the vector from 
circulating antibodies, allowing for repeated administration of vector. Shielding with PEG inhibits 
CAR-mediated binding to cells in vitro [105]. However, it generally does not affect CAR-independent 
infection of liver in vivo, with the exception that high molecular weight PEG coated virions could not 
exit  through  the  fenestrae  of  the  liver  endothelium  and  were  physically  unable  to  gain  access  to 
hepatocytes [106,107]. Ligands for receptors present on tumor cells or tumor endothelium (e.g. EGF, 
FGF-2,  VEGF)  were  coupled  to  PEG-coated  virions  to  specifically  target  the  vector  to  
tumors [108-110].  
8. Preventing the anti-viral immune response 
The recent use of immunocompetent animal models by a number of investigators has allowed the 
effect of the host immune system on the oncolytic Ad vector-infected tumor to be studied in detail. The 
immune system could have at least two effects on the efficacy of oncolytic Ad vectors: the developing 
anti-virus immunity can eliminate the vector, thus decreasing efficacy, or the infection of the tumor by 
the vector can change the otherwise immunosuppressive environment of the tumor and induce the 
development  of  anti-tumor  immune  response,  thus  enhancing  efficacy.  We  have  addressed  these 
questions by employing the Syrian hamster animal model.  
We compared the efficacy of VRX-007 injected intratumorally into syngeneic kidney cancer tumors 
in immunocompetent and immunosuppressed hamsters. We demonstrated that the immunocompetent 
hamsters quickly developed anti-vector immunity that significantly decreased the efficacy of VRX-007 
[28]. In immunocompetent hamsters, the vector was effective initially in suppressing the growth of 
tumors following intratumoral injection, but then as anti-vector immunity developed, the efficacy was 
decreased  and  the  tumors  resumed  growth  typically  after  2-4  weeks  following  vector  injection. 
Repeated injection of the vector after tumors had started growing again did not decrease the growth 
rate. In contrast, in immunosuppressed animals the efficacy of the vector was sustained [28,111,112]. 
To  explain  the  apparent  contradiction  with  results  obtained  in  clinical  trials,  i.e.  that  circulating 
neutralizing antibodies to Ad have no effect on the efficacy of intratumorally injected vector [50,54], 
we tested the efficacy of VRX-007 in kidney tumor-bearing hamsters that were either naïve regarding 
exposure to Ad or were immunized with the virus, and then either left untreated or immunosuppressed 
[111]. Hamsters that were immunized with Ad had very high anti-Ad neutralizing antibody levels to 
start with, but even naïve, immunocompetent animals produced neutralizing antibodies by seven days 
after intratumoral injection of the vector, and these antibodies were present in the tumor as well [111]. Viruses 2010, 2                           
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Consistently, there was no significant difference between the efficacy of VRX-007 in these two groups 
of animals, i.e., the vector suppressed the growth of tumors following intratumoral injection for 2-3 
weeks,  but  then  the  tumor  growth  resumed.  However,  when  the  vector  was  injected  into 
immunosuppressed animals, the efficacy of VRX-007 was much decreased in the hamsters that were 
immunized  before  immunosuppression  and  had  neutralizing  antibodies  at  the  time  of  VRX-007 
injection compared to the naïve, immunosuppressed hamsters that did not have antibodies at the start 
of treatment and had no potential to raise them. Thus, we conclude that naïve animals, and most likely 
patients, develop anti-Ad immunity very quickly, which will impede the anti-tumor efficacy of an 
oncolytic Ad vector, and that the presence of pre-existing immunity does not have a great impact on 
anti-tumor  efficacy  [111].  Our  data  also  indicate  that  repeated  cycles  of  vector  injection  into 
immunocompetent patients will probably not increase the efficacy of the treatment. However, this 
interpretation does not, and cannot account for the great variability within patient populations, which 
can introduce unknown factors that might influence the immune response and vector efficacy. 
Pre-existing  immunity,  however,  can  have  a  beneficial  effect  on  the  safety  of  oncolytic  Ads. 
Previous  exposure  to  Ad  or  passive  immunization  using  hyperimmune  serum  can  prevent  the 
dissemination of the vector to normal organs, and it can prevent lethal intravenous challenge with Ad5 
even in immunosuppressed animals [62].  
Besides of scientific interest, these finding may have some relevance in designing cancer treatment 
regimes as well. As many chemotherapeutic drugs are immunosuppressive, it could be feasible to 
devise a protocol to take advantage of this effect, i.e., start the chemotherapy treatment before injecting 
the Ad vector. In fact, it is conceivable that the enhanced efficacy of oncolytic Ads in combination 
with chemotherapy resulted from immunosuppression of the patient. 
9. Armed oncolytic Ad vectors 
While the premise of cancer therapy with oncolytic Ads is that the vector will replicate in tumor 
cells  and  kill  them  through  the  lytic  replication  cycle,  this  effect  can  be  enhanced  by  expressing  
anti-cancer  therapeutic  molecules  (i.e.  “arming”  the  vector).  This  can  partially  overcome  the 
attenuation  of  vectors  that  have  lost  their  potency  because  of  multiple  genetic  modifications 
implemented to achieve tumor-specific replication. The most common site to insert transgenes is in 
place  of  the  deleted  E3  region,  where  one  can  take  advantage  of  the  native  viral  promoters  and 
differential splicing in the viral genome to express these genes either in the early or the late phase of 
Ad replication [113]. Alternatively, transgenes can be expressed from strong constitutive or inducible 
foreign  promoters.  As  the  infected  cell  is  expected  to  be  killed  by  the  oncolytic  Ad,  therapeutic 
molecules in armed oncolytic Ads are usually secreted or have a bystander effect to affect cells beyond 
the  one  that  is  infected  by  the  virus.  There  are  numerous  therapeutic  molecules  expressed  from 
oncolytic Ads; many of them were adopted from cancer therapy treatment with RD viral vectors. 
These molecules can be grouped by function; the groups are discussed below. 
10. Molecules enhancing vector spread 
As the proposed mechanism of action for oncolytic Ads relies on the production of progeny virus 
and the spread of infection through a solid tumor, it is clear that any increase in vector spread will 
result in an increase in anti-tumor efficacy. To speed up the first step in vector spread, namely the Viruses 2010, 2                           
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egress of progeny virions from the infected cells, researchers have over-expressed the Ad ADP protein 
[13,63,65,114]. Another way to facilitate virus release from infected cells is to introduce a deletion into 
the e3 gp19K gene [58]. Others employed a fusogenic protein from an enveloped virus which causes 
the  membrane  of  the  infected  cell  to  fuse  with  neighboring  cells,  resulting  in  formation  of  large 
syncytia, thus enhancing cell-to-cell spread [115]. Once the infected cells have lysed, virus is released 
to the intercellular matrix and can infect nearby cells. As discussed above, tumor architecture that 
contains  necrotic  areas  and  fibrotic  stroma  often  hampers  the  spread  of  the  vector  beyond  the 
immediate vicinity of infection site [56]. To make the tumor microenvironment more permeable, a 
research  group  expressed  the  peptide  hormone  relaxin  from  their  oncolytic  Ad  vector  [116,117]. 
Relaxin increases the production of certain matrix metalloproteases and decreases the production of 
collagen. The intratumoral spread and the anti-tumor efficacy of the relaxin-expressing vector were 
significantly better than those of the parental vector.  
11. Prodrug-converting enzymes 
Prodrug-converting  enzymes,  enzymes  that  convert  non-toxic  prodrugs  to  the  active  form  (e.g. 
thymidine kinase, cytosine deaminase, nitroreductase [118,119]), have been used in RD vectors for a 
long time, and can be adapted readily to use in oncolytic vectors. With this kind of therapy normal 
cells  do  not  get  exposed  to  the  toxic  product,  because  although  the  prodrug  is  administered 
systemically, it is processed into the toxic drug only in the vector-infected tumor cells. This ensures 
high local concentration of the drug, because the converted drug then can leave the infected cell and be 
taken up by neighboring cells, thereby causing a local bystander effect. Besides being toxic to cancer 
cells, thymidine kinase can be also used to image the vector-infected tissues by injecting a PET or 
SPECT tracer substrate [120]. The timing of the administration of the prodrug is critical, because many 
of their products are chain-terminator nucleotide analogues, and will prevent virus replication. Thus, 
these can be considered “suicide gene” safety measures, which, when the prodrug is injected, will stop 
runaway virus infection. 
12. Immunomodulatory molecules 
Tumor  cells  have  evolved  multiple  tactics  to  evade  the  immune  system:  they  can  express 
immunosuppressive cytokines, down-regulate Major Histocompatibility Class I molecules, and even 
express Fas ligand to kill reactive cytotoxic lymphocytes. Thus, the tumor microenvironment prevents 
the immune system from eradicating tumors, even those that express tumor antigens [121]. Infection of 
the tumor with Ads elicits a strong inflammatory immune response [122], which may overcome this 
immunosupression.  This  immune  response  can  be  improved  further  by  expressing  cytokines  and 
chemokines that are being investigated in cancer immunotherapy (reviewed in [123]) from the virus. 
The  immunomodulatory  transgenes  tested  so  far  include  GM-CSF  to  stimulate  the  production  of 
antigen presenting cells [124,125], Fas ligand and IL-27 to facilitate antigen presentation on dendritic 
cells  (DCs)  [126],  interferons  α, β,  and  γ for  direct  anti-tumor  activity  and  to  induce  a  pro-
inflammatory effect [127-129], the chemokine RANTES for recruiting DCs and T lymphocytes [130], 
and IL-12 to activate T lymphocytes [131]. To overcome the defects in antigen presentation that many 
tumor cells have acquired, researchers developed an oncolytic Ad that expresses the chaperone hsp70 
in the tumor cell [132]. The hsp70 molecule will be “loaded” with the peptides of the infected cell, Viruses 2010, 2                           
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among them peptides that could serve as epitopes of tumor antigens. When the infected cell is lysed by 
the RC Ad vector, the DCs will take up the peptide-chaperone complexes and present the peptides on 
Class II molecules, thus raising an immune reaction to the tumor. 
Most of the experiments with immunomodulatory molecules expressed from oncolytic Ads were 
performed in vitro, or using human xenografts in immunodefective mice, in which the transgene may 
not be functional, or using immunocompetent mice with syngeneic tumors, in which the vector does 
not  replicate.  With  the  recent  development  of  immunocompetent,  permissive  animal  models, 
researchers can test these vectors in a more adequate system. An oncolytic Ad expressing human 
interferon α showed increased efficacy against syngeneic kidney tumors in Syrian hamsters [133]. As 
an  added  benefit,  the  expression  of  interferon  α  dramatically  decreased  vector  toxicity  [129,133]. 
Another  research  group  demonstrated  that  a  human  GM-CSF  expressing  oncolytic  Ad  eradicated 
subcutaneous  pancreatic  tumors  in  hamsters,  and  that  the  hamsters  that  became  tumor  free  after 
treatment with the vector developed anti-tumor immunity [55].  
These transgenes will presumably increase the host immune response to the infecting vector as well; 
although this will hasten the elimination of the vector and thus work against the original premise of 
how oncolytic viruses work, still, the end result may be enhanced oncolysis. 
13. Molecules with direct anti-tumor effect 
Cytotoxic molecules can be expressed in the oncolytic Ad-infected tumor in order to ensure high 
intratumoral concentration and at the same time avoid exposing the normal cells of the body to these 
highly toxic substances. 
Several oncolytic Ad vectors expressing apoptosis-inducing death ligands like TNFα, Fas ligand, 
and TRAIL have been described [126,133-135]. This approach, similarly to RC Ads combined with 
immunotherapy, may have a deleterious effect on vector replication and spread. The secreted protein 
can kill uninfected tumor cells surrounding the infected cell, and thus creating a “firewall” of dead 
cells that can prevent virus spread. 
14. Anti-angiogenic agents 
Tumor neovasculature presents a very promising target within the tumor. The uncontrolled growth 
of tumors causes hypoxic conditions, which in turn stimulates the formation of blood vessels, further 
aided by the secretion of pro-angiogenic factors by some tumors. Interfering with tumor angiogenesis 
will deprive the tumor of nutrients and oxygen (reviewed in [136]). As neo-endothelium expresses 
high levels of αvβ3 integrins [137], one of the cellular co-receptors for Ad binding, Ads are naturally 
targeted  to  newly  formed  blood  vessels.  This  effect  can  be  further  enhanced  by  expressing  anti-
angiogenic molecules including endostatin [138], antagonists of VEGF [139,140], certain cytokines, 
(e.g. type I interferons [127,129], and MDA-7/IL-24 [141]) from oncolytic Ads. There is a possibility 
of synergism with this latter approach, as the target of the transgene is different from the cancer cells 
themselves that are being destroyed by virus replication.  Viruses 2010, 2                           
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15. Conclusion 
It has been proven through numerous preclinical and clinical experiments that oncolytic Ad vectors 
are safe to use, especially with patients with pre-existing immunity. The vectors’ efficacy can be 
increased through multiple methods that include modifying the vector itself, employing better delivery 
techniques, or preventing the elimination of the vector by the host immune system. As the mechanism 
of action of oncolytic Ads is different from that of conventional cancer treatment, RC Ad treatment can 
be incorporated into existing treatment regimes, which will likely increase efficacy of treatment over a 
single modality. Thus, oncolytic Ads will be an additional treatment option to combat cancer. 
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